Related references
Note: Only part of the references are listed.Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
R. A. Ibrahim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
Kevin P. Murphy et al.
Oncology Research and Treatment (2016)
Ipilimumab-Induced Hepatitis on 18F-FDG PET/CT in a Patient With Malignant Melanoma
Roy A. Raad et al.
CLINICAL NUCLEAR MEDICINE (2015)
Antitumor Granuloma Formation by CD4+ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab
Jason J. Luke et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
Amanda D. Henderson et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2015)
Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade
Shirwa Sheik Ali et al.
JAMA DERMATOLOGY (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
C. Lebbe et al.
ANNALS OF ONCOLOGY (2014)
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
V. Chiarion-Sileni et al.
BRITISH JOURNAL OF CANCER (2014)
First report of ipilimumab-induced Grover disease
J. Munoz et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
Magnus Pedersen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents
A. Picchianti Diamanti et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis
Yosef Chodakiewitz et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2014)
Ipilimumab-Induced Immunomediated Adverse Events Possible Pitfalls in 18F-FDG PET/CT Interpretation
Laura Gilardi et al.
CLINICAL NUCLEAR MEDICINE (2014)
Kidney injuries related to ipilimumab
Hassane Izzedine et al.
INVESTIGATIONAL NEW DRUGS (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy
Nalini K. Vudattu et al.
JOURNAL OF IMMUNOLOGY (2014)
Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma
Pauline du Rusquec et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma
Rachel L. Kyllo et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Mario E. Lacouture et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash
Neelima N. Nallapaneni et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Entering the mainstream of cancer treatment
Steven A. Rosenberg
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Bing Liao et al.
NEURO-ONCOLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ipilimumab-Induced Orbital Inflammation Resembling Graves Disease With Subsequent Development of Systemic Hyperthyroidism From CTLA-4 Receptor Suppression
Gary E. Borodic et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2014)
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Hye Sun Kuehn et al.
SCIENCE (2014)
Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4
Barbara L. Goldstein et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports
Joke Marlier et al.
ENDOCRINE (2014)
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
Elizabeth McElnea et al.
ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY (2014)
Ipilimumab-Associated Colitis: CT Findings
Kyung Won Kim et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2013)
Orbital myositis associated with ipilimumab
M. Lecouflet et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2013)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
D. McDermott et al.
ANNALS OF ONCOLOGY (2013)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
J. Delyon et al.
ANNALS OF ONCOLOGY (2013)
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
P. Queirolo et al.
CANCER INVESTIGATION (2013)
Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Igor Z. Barjaktarevic et al.
CHEST (2013)
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
Caroline Robert et al.
CLINICAL CANCER RESEARCH (2013)
Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab
Bernies van der Hiel et al.
CLINICAL NUCLEAR MEDICINE (2013)
Melanoma-Associated Retinopathy Treated with lpilimumab Therapy
A. Audemard et al.
DERMATOLOGY (2013)
Sarcoidosis complicating anti-cytotoxic T-Iymphocyte-associated antigen-4 monoclonal antibody biotherapy
Claire Tissot et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy
A. Lammert et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2013)
Lymphocytic Colitis Secondary to Ipilimumab Treatment
Alejandro Garcia-Varona et al.
INFLAMMATORY BOWEL DISEASES (2013)
Ipilimumab-induced Perforating Colitis
Kisha A. Mitchell et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
David R. Minor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
A Severe Case of Ipilimumab-Induced Guillain-Barre Syndrome Revealed by an Occlusive Enteric Neuropathy: A Differential Diagnosis for Ipilimumab-Induced Colitis
Caroline Gaudy-Marqueste et al.
JOURNAL OF IMMUNOTHERAPY (2013)
The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
Kira Minkis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
Ross B. Reule et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
MULTIFOCAL RADICULONEUROPATHY DURING IPILIMUMAB TREATMENT OF MELANOMA
Georgios Manousakis et al.
MUSCLE & NERVE (2013)
Association Between Ipilimumab and Celiac Disease
Nicole M. Gentile et al.
MAYO CLINIC PROCEEDINGS (2013)
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Sebastian G. Bernardo et al.
MELANOMA RESEARCH (2013)
Ipilimumab-induced acute severe colitis treated by infliximab
Cecile Pages et al.
MELANOMA RESEARCH (2013)
Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy
Sofya Pintova et al.
MELANOMA RESEARCH (2013)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J. Voskens et al.
PLOS ONE (2013)
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
Ahmad Tarhini
SCIENTIFICA (2013)
Severe colitis while responding to ipilimumab in metastatic melanoma
Marije Slingerland et al.
ACTA ONCOLOGICA (2012)
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
Riccardo Danielli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Ipilimumab-Induced Colitis on FDG PET/CT
Ashima Lyall et al.
CLINICAL NUCLEAR MEDICINE (2012)
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
David E. Kleiner et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
ASSOCIATION OF IPILIMUMAB THERAPY FOR ADVANCED MELANOMA WITH SECONDARY ADRENAL INSUFFICIENCY: A CASE SERIES
Le Min et al.
ENDOCRINE PRACTICE (2012)
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
Agata Juszczak et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Enterocolitis in a Patient Being Treated With Ipilimumab for Metastatic Melanoma
Christine Koch et al.
GASTROENTEROLOGY (2012)
Severe meningo-radiculo-nevritis associated with ipilimumab
Flavie Bompaire et al.
INVESTIGATIONAL NEW DRUGS (2012)
Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
Michela Maur et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Gregoire Berthod et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
Wouter V. Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Hyponatremia associated with Ipilimumab-induced hypophysitis
Zachary R. Barnard et al.
MEDICAL ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
S. Wilgenhof et al.
ANNALS OF ONCOLOGY (2011)
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Autoimmunity and treatment outcome in melanoma
Marna G. Bouwhuis et al.
CURRENT OPINION IN ONCOLOGY (2011)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Katarzyna D. Chmiel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
Kaan Harmankaya et al.
MEDICAL ONCOLOGY (2011)
Hemophilia A Induced by Ipilimumab
Julie Delyon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma
S Ahmad et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Atypical Clinical Response Patterns to Ipilimumab: Four Case Studies of Advanced Melanoma
Blanca Ledezma et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Christy Ralph et al.
CLINICAL CANCER RESEARCH (2010)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
Bradley C. Carthon et al.
CLINICAL CANCER RESEARCH (2010)
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
James D. Lord et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System?
Yun Kyung Lee et al.
SCIENCE (2010)
Clinical Studies With Anti-CTLA-4 Antibodies in Non-melanoma Indications
Luana Calabro et al.
SEMINARS IN ONCOLOGY (2010)
Ipilimumab-Induced Hypophysitis: MR Imaging Findings
K. J. Carpenter et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2009)
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Gary Hunter et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2009)
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
David R. Minor et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Ilyssa O. Gordon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
A. Eckert et al.
DERMATOLOGY (2009)
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells
Helene Bour-Jordan et al.
IMMUNOLOGICAL REVIEWS (2009)
Neutropenia in a Patient Treated With Ipilimumab (anti-CTLA-4 Antibody)
Mojtaba Akhtari et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma A Case Report
Shailender Bhatia et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient
Katharina C. Kaehler et al.
MELANOMA RESEARCH (2009)
Anti-CTLA4 Antibody-Induced Lupus Nephritis.
Fouad Fadel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade
Willemijn B. Breunis et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) - A novel strategy for the treatment of melanoma and other malignancies
Steven J. O'Day et al.
CANCER (2007)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas et al.
ONCOLOGIST (2007)
Transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade
Stephanie A. Shaw et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent
SH Jaber et al.
ARCHIVES OF DERMATOLOGY (2006)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunotherapy: past, present and future
TA Waldmann
NATURE MEDICINE (2003)
Share Paper
